3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Status
Unknown
2
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Head & Neck
11
Gastrointestinal
3
Tumor-Agnostic
2
Thoracic
2
Sarcoma
2
Breast
1
Conditions
Neoplasms
21
Neoplasm Metastasis
10
Carcinoma, Squamous Cell
2
Carcinoma
2
Neoplasms, Unknown Primary
1
Neoplasms, Second Primary
1
Interventions
Paclitaxel
9
Carboplatin
9
pembrolizumab
7
Radiotherapy
7
Cisplatin
5
Axitinib
4
Pemetrexed
3
Nivolumab
3
trifluridine tipiracil drug combination
2
regorafenib
2
osimertinib
2
fludarabine
2
dacomitinib
2
catumaxomab
2
Trastuzumab
2
Sunitinib
2
Radiotherapy, Intensity-Modulated
2
Nurses
2
Interleukin-2
2
Gemcitabine
2
Docetaxel
2
Cyclophosphamide
2
Cetuximab
2
Bevacizumab
2
Albumin-Bound Paclitaxel
2
130-nm albumin-bound paclitaxel
2
vatalanib
1
temsirolimus
1
sovateltide
1
selinexor
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Carcinoma
×
Cetuximab
×
Tumor-Agnostic
×
Clear all
NCT01855451
2022-11-18
HPVOropharynx
Trans Tasman Radiation Oncology Group
Phase 3
Unknown
189 enrolled
NCT00894569
2009-05-14
PACET-CUP
Heidelberg University
Phase 2
Unknown
150 enrolled